It’s 100 percent fatal, hits its victims in the prime of their lives and has companies with prospective treatments either shutting down or spinning their wheels with trial holds and failures. Huntington’s disease might just top the list of intractable neurodegenerative diseases.
New research out of McMaster University found a recently abandoned Bayer compound halted the growth of an aggressive form of pediatric medulloblastoma in mouse models.
Surrozen announced it paused its Phase I study Crohn’s disease and ulcerative colitis as several healthy participants showed increased levels of liver enzymes.
It has been a lucrative Tuesday for Jnana Therapeutics after it forged a second small molecule discovery and development collaboration and licensing agreement with Roche valued up to $2 billion.
Roche announced its investigational antibody gantenerumab failed to meet the primary endpoints in GRADUATE I and II – two Phase III studies in Alzheimer’s disease.
“We are surprised and disappointed” that the drug did not show superiority over the placebo, Chief Executive Officer John Kollins said.
The FDA approved AstraZeneca’s Imfinzi (durvalumab) in combination with Imjudo (tremelimumab) and platinum-based chemotherapy Thursday for adult patients with metastatic non-small cell lung cancer (NSCLC).
The U.S. national public health agency said on Friday that Omicron subvariants BQ.1 and BQ.1.1 were estimated to account for about 44.2% of COVID-19 cases in the country for the week ending Nov. 12, compared with 32.6% in the previous week.
Seagen is on a roll this week. After naming David R. Epstein as its new CEO, the Washington-based biotech announced that Adcetris (brentuximab vedotin) has been given FDA approval for the treatment of children aged two years and above with high-risk classical Hodgkin lymphoma.
San Diego’s Lipidio Pharmaceuticals, a company that is focused on dermatological and metabolic diseases, raked in $20 million from a trio of well-known biopharma executives in a Series A extension.